All In Biotech

Drug Trial Radar · NCT00537420

A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients

Last checked: Nov 20, 2026Latest source record: Sep 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 551 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

551

Actual

Start

Oct 2007

Primary completion

Jul 2008

Study completion Sep 2008

Sponsor

Sponsor type
Industry
First posted
Oct 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.

Conditions

  • Obesity

Interventions

  • Nasal PlaceboDrug

    Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.

  • Placebo CapsuleDrug

    Placebo capsules will be taken once daily with or without food.

  • PYY3-36Drug

    Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.

  • PYY3-36Drug

    Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.

  • PYY3-36Drug

    Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.

  • SibutramineDrug

    Sibutramine will be taken once daily with or without food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of increasing nasal PYY3 36 dosing on weight loss post 24 weeks of treatmentTime frame: 24 Weeks

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Peoria, Arizona

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Phoenix, Arizona

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Anaheim, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Beverly Hills, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Carmichael, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Orange, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Sacramento, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    San Diego, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    San Diego, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    San Francisco, California

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Pembroke Pines, Florida

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Atlanta, Georgia

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Augusta, Georgia

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Evansville, Indiana

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Valparaiso, Indiana

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Baton Rouge, Louisiana

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Brooklyn Center, Minnesota

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Las Vegas, Nevada

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Manlius, New York

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Charlotte, North Carolina

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Raleigh, North Carolina

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Cleveland, Ohio

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Reading, Pennsylvania

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Greer, South Carolina

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Mt. Pleasant, South Carolina

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Austin, Texas

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    San Antonio, Texas

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Temple, Texas

  • For additional information regarding investigative sites for this trial, contact 1-425-415-3011

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.